Evaxion advances its EVX-01 melanoma program with three-year efficacy data at ESMO 2026, highlighting durability and standalone potential.The Manila Times
On the methodological front, Paean offers significant speedups for transcriptome quantification via GPU-CPU parallelization, while new research explores NMD inhibition to preserve neoantigen expression and chemically synthesized RNA oligonucleotides to accelerate vaccine manufacturing timelines.PubMedPubMedPubMed
The data stems from a one-year extension of the phase 2 trial evaluating EVX-01 in patients with advanced melanoma (skin cancer). In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not admini…
Datavault AI Announces Tokenization of Available Infrastructure’s... Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results ... Hyperscale Data Begins Installation of Omnipresent Robotics OPR-R... Faraday Future Showcases Its EAI Robot World Across Three High-Le... Lian…
The nonsense-mediated mRNA decay (NMD) is a highly conserved post-transcriptional mRNA screening system that is vital in keeping cellular integrity by targeting aberrant mRNAs harboring premature termination codons (PTCs) for degradation. Although traditionally considered as a sy…
Personalized mRNA neoantigen vaccines demonstrate great potential in cancer therapy, but their customization typically requires more than three months, risking the loss of the optimal therapeutic window for patients. This delay is primarily due to the reliance of current mRNA vac…
Relevant work from earlier we're still surfacing — not today's news.